STOCK TITAN

Odyssey Group Intl Inc - ODYY STOCK NEWS

Welcome to our dedicated news page for Odyssey Group Intl (Ticker: ODYY), a resource for investors and traders seeking the latest updates and insights on Odyssey Group Intl.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Odyssey Group Intl's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Odyssey Group Intl's position in the market.

Rhea-AI Summary
Odyssey Health, Inc. (ODYY) reports $13.2 million in net income and $8.7 million in total stockholder equity for the quarter ended January 31, 2024. The increase is attributed to the sale of neurological assets to Oragenics, Inc. The company received eight million shares of Oragenics Series F preferred stock, enhancing its balance sheet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
none
-
Rhea-AI Summary
Odyssey Health, Inc. (OTCQB:ODYY) announces the closing of an Asset Purchase Agreement with Oragenics, Inc. (OGEN:NYSE American) for the acquisition of Odyssey's proprietary assets related to its neurological drug therapy platform. The agreement includes cash payments, issuance of preferred stock, and collaboration for the development of drug candidates for treating concussion and Niemann Pick Disease Type C. Odyssey's lead drug candidate, ONP-002, has shown promising results in preclinical and Phase 1 human clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
none
-
Rhea-AI Summary
Odyssey Health, Inc. (OTCOB:ODYY) received stockholder approval for the sale of its neurological drug platform technology to Oragenics, Inc. at a Special Meeting on December 7, 2023. The asset purchase agreement includes a $1,000,000 consideration, with $500,000 already received and an additional $500,000 payment upon the successful proxy vote. Odyssey will also receive eight million shares of Oragenics Convertible Preferred Class F stock. The transaction is expected to close before the end of the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
none
Rhea-AI Summary
Odyssey Health, Inc. (OTCQB:ODYY) selects Syneos Health® to support its Investigational New Drug (IND) Application for its lead drug candidate ONP-002, targeting mild Traumatic Brain Injury (mTBI). Syneos Health will provide guidance and review of pre-clinical and clinical data, as well as support for the Phase II clinical trial design in the US. The partnership aims to position the study for success by leveraging Syneos Health's expertise and regulatory affairs solutions (GRAS) for neurological drugs and intranasal devices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
none
-
Rhea-AI Summary
Odyssey Health, Inc. (OTCQB:ODYY) will hold a webcast on November 16, 2023, to provide an update on the company, recap its progress, and discuss the sale of the neurological technology platform to Oragenics, Inc. Participants can join via web link or phone. The company will receive 8 million shares of Oragenics, Inc. Series F Preferred convertible stock as part of the asset purchase agreement. The Special Meeting related to the sale will be held on December 7, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.75%
Tags
none
-
Rhea-AI Summary
Odyssey Health provides an update on its Asset Purchase Agreement with Oragenics
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.65%
Tags
none
Rhea-AI Summary
Oragenics to acquire Odyssey Health's assets related to neurological drug therapies and technologies, including drug candidates for treating mild traumatic brain injury and Niemann Pick Disease Type C, as well as a proprietary powder formulation and nasal delivery device. The transaction includes $1.0 million in cash payments and eight million shares of Oragenics' Series F Convertible Preferred Stock. The deal is expected to close in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.71%
Tags
acquisition
-
Rhea-AI Summary
Oragenics to acquire Odyssey Health's assets related to neurological drug therapies and technologies, including drug candidates for treating mild traumatic brain injury and Niemann Pick Disease Type C, as well as a proprietary powder formulation and nasal delivery device. The transaction includes $1.0 million in cash payments and eight million shares of Oragenics' Series F Convertible Preferred Stock. The deal is expected to close in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13%
Tags
acquisition
-
Rhea-AI Summary
Odyssey Health, Inc. (OTCQB: ODYY) has commenced trading on the OTCQB Market after up-listing from the OTC Pink Market. The up-listing expands the audience of investors that can invest in the company. Odyssey is focused on developing nasal delivery of proprietary compounds to treat neurological disorders, including mTBI. The company aims to drive enhanced clinical efficacy from its products and create shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.86%
Tags
none
Rhea-AI Summary
Odyssey Health, Inc. presented at the Military Health System Research Symposium (MHSRS) on their novel pharmaceutical, ONP-002, for brain-targeted delivery in mild traumatic brain injury (mTBI). The poster included positive preclinical data and safety findings from Phase I clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.96%
Tags
none
Odyssey Group Intl Inc

OTC:ODYY

ODYY Rankings

ODYY Stock Data

3.37M
81.32M
19.33%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Las Vegas